产品
编 号：F215997
分子式：C22H32ClN3O7
分子量：485.96
分子式：C22H32ClN3O7
分子量：485.96
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
结构图
CAS No: 179474-85-2
产品详情
生物活性：
Prucalopride succinate is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride succinate improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride succinate also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride succinate can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer.
体内研究：
Prucalopride succinate (5 mg/kg, 皮下注射) 可增加大鼠前额皮质乙酰胆碱和组胺水平。Prucalopride succinate (5, 10 μg/kg;口服;每天一次连续两周) 可缩短DM模型结肠转运时间，促进结肠神经干细胞和神经元再生。Prucalopride succinate (5, 10 μg/kg;口服;每天一次连续两周)可促进结肠神经干细胞分化，激活胶质蛋白表达，一定程度上促进神经元损伤的恢复。Animal Model:Diabetes mellitus (DM) rat models
Dosage:5 μg/kg, 10 μg/kg
Administration:Oral gavage, single daily for 2 weeks.
Result:Accelerated colonic movement and shortened the colonic transit time, and markedly increased the expression levels of Ki67 .Increased expression of SOX10 in the columnar epithelial nuclei and enteraden (when at 5 μg/kg), and in the columnar epithelial cells, the nuclei of lamina propria cells and enteraden (when at 10 μg/kg). Significantly increased Nestin expression, which concentrated in columnar epithelial cells and the mesenchyme. (Nestin:a marker of enteric neural stem cells in the ENS).
体外研究：
Prucalopride succinate (10 μM; 24, 48, 72 h) 在A549细胞中显示抗增殖活性。Prucalopride succinate 诱导A549/A427细胞自噬和凋亡，降低磷酸化蛋白激酶B (AKT)和哺乳动物雷帕霉素靶蛋白(mTor)的表达。
Prucalopride succinate is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride succinate improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride succinate also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride succinate can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer.
体内研究：
Prucalopride succinate (5 mg/kg, 皮下注射) 可增加大鼠前额皮质乙酰胆碱和组胺水平。Prucalopride succinate (5, 10 μg/kg;口服;每天一次连续两周) 可缩短DM模型结肠转运时间，促进结肠神经干细胞和神经元再生。Prucalopride succinate (5, 10 μg/kg;口服;每天一次连续两周)可促进结肠神经干细胞分化，激活胶质蛋白表达，一定程度上促进神经元损伤的恢复。Animal Model:Diabetes mellitus (DM) rat models
Dosage:5 μg/kg, 10 μg/kg
Administration:Oral gavage, single daily for 2 weeks.
Result:Accelerated colonic movement and shortened the colonic transit time, and markedly increased the expression levels of Ki67 .Increased expression of SOX10 in the columnar epithelial nuclei and enteraden (when at 5 μg/kg), and in the columnar epithelial cells, the nuclei of lamina propria cells and enteraden (when at 10 μg/kg). Significantly increased Nestin expression, which concentrated in columnar epithelial cells and the mesenchyme. (Nestin:a marker of enteric neural stem cells in the ENS).
体外研究：
Prucalopride succinate (10 μM; 24, 48, 72 h) 在A549细胞中显示抗增殖活性。Prucalopride succinate 诱导A549/A427细胞自噬和凋亡，降低磷酸化蛋白激酶B (AKT)和哺乳动物雷帕霉素靶蛋白(mTor)的表达。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备